Lysyl oxidase homologue 2 (LOXL2) inhibitors have been reported in a Yuhan Corp. patent as potentially useful for the treatment of idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), chronic kidney disease and cirrhosis.

Petra Pharma Corp. has patented phosphatidylinositol 3-kinase α (PI3Kα, PIK3CA) (H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Caraway Therapeutics Inc. has divulged mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of metabolic diseases, aging, cancer, ciliopathy, neurodegeneration and muscle disorders.

Michigan State University has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).

Palacky University has disclosed platinum complexes reported to be useful for the treatment of multiple myeloma.

Lead Discovery Center GmbH and Qli5 Therapeutics GmbH have described macrocyclic compounds acting as proteasome subunit β type-5 (PSMB5) inhibitors reported to be useful for the treatment of cancer, infections, inflammatory disorders, myasthenia gravis and transplant rejection.

Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.

Janssen Pharmaceutica NV has identified IL-17 production inhibitors reported to be useful for the treatment of inflammatory disorders.